Company news
Larimar Therapeutics, Inc. news in 2020
Larimar Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update
December 7, 2020
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
November 9, 2020
Larimar Therapeutics Announces Formation of Scientific Advisory Board
October 12, 2020
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
August 10, 2020
Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia
July 27, 2020
Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia
July 19, 2020
Decks in 2020
- Investor Presentation (December 2020)
Investor deck · 31 slides · Dec 8, 2020
- Investor Presentation (November 2020)
Investor deck · 28 slides · Nov 10, 2020
- Investor Presentation (August 2020)
Investor deck · 23 slides · Aug 6, 2020
- Investor Presentation (June 2020)
Investor deck · 21 slides · Jun 3, 2020
- Zafgen — Merger or Acquisition (February 2020)
Merger or acquisition · 24 slides · Feb 5, 2020
- Zafgen — Merger or Acquisition (February 2020)
Merger or acquisition · 22 slides · Feb 5, 2020
- Zafgen — Merger or Acquisition (January 2020)
Merger or acquisition · 19 slides · Jan 13, 2020